Hi guys, just want to give you some interesting read on a Japanese day trader called CIS, whose stryr featured in Bllomberg news a while back:

http://www.bloomberg.com/news/2014-09-25/m...ion-trades.html

Points to note:

1) Fundamentals is useless in short term intra-day trading.

2) He monitors top 300 most traded stocks...

3) He said 'buy when people are buying and sell when people are selling'...

4) Hes an obvious momentum trader...means he monitor if theres a sudden big volume of bidding or selling price coming...he follows the big money when it enters and when it goes out.

5) Let his winner rides and cut his losers fast.

6) Complicated technical analysis or fundamentals waste your time in analyzing and executing....he prefers the numbers on the market to tell the story and re3acts within seconds....

Im a noob in stock market so pls spare me from any bad bashing uncle gark or pink spider  gor...

Yes, the problem with fast momentum trading is that you can never beat the superfast algorithms.

Guys, what do u think of this? Fundamentals and Technical points of view.

Thanks

Somebody is bound to ask what stock it that? HOVID?

Aiyo

See the chart and the financials first la...so fast ask stock name for what

Guys, what do u think of this? Fundamentals and Technical points of view.

Thanks

- I won't do Q1 annualized. Every quarter in a FY is different.
- FY14 results not so great, but this is also true for many other stocks. Do you foresee better results ahead?
- Penny stock, likely to be volatile.
- Can't commend from technical perspective

Pharma companies earnings not too volatile quater to quarter la

Revenue still growing, 5-6% growth so should be sustainable.  Weak Ringgit should do them good in coming quarters

Do u think good for buy and hold?

5-6% not considered fast grower. DY ok but not great.
The decision is yours 

Got stock name only Boon3 will go dig up company articles then post together with his analysis....

The prices of some drugs increased 20% to 50% this year alone, with most companies adjusting their prices twice over the last 12 months, according to the Malaysian Community Pharmacy Guild.

MCPG president Wong Sie Sing said the “normal” annual increase is between 5% and 10% but with the Goods and Services Tax coming into effect next April, consumers have to brace themselves for another round of hikes of 10% to 40% across the board.

“We sympathise with consumers and are working with the Government and stakeholders to ensure affordable drug prices,” he said.

MCPG, which represents more than 2,000 community pharmacies employing some 2,500 pharmacists, is urging the Government to set up a national health financing authority to control medical costs.

“Otherwise, drug prices could rise very rapidly,” Wong said.

There is now no price control mechanism for pharmaceuticals.

Malaysian Pharmaceutical Society (MPS) president Datuk Nancy Ho said the rising prices of both imported and generic drugs could force many to stop taking their medicine.

MPS is the national association for pharmacists in Malaysia, with some 4,000 members.

Ho said: “The rise in drug prices could be due to increased costs of raw materials, equipment, labour and transportation as well as the weak currency exchange, which impacts all sectors.

“GST will worsen the situation further as almost all newer medicines with better results and less side effects will be taxed 6%.”

Malaysian Medical Association president Dr H. Krishna Kumar said the cost of all drugs had risen higher than the inflation rate, warning that even tax-exempted drugs would go up with the increase in the cost of transportation and storage which are taxed.

Academy of Medicine of Malaysia council member Datuk Dr N.K.S. Thar­masee­lan said drug prices had been increasing every six months at an average of 10% to 20% generally.

“Newer drugs to treat diabetes and hypertension have become unaffordable. Though they are the best, public hospitals do not dish out such drugs as they are pricey,” he said.

Dr Tharmaseelan, who is an MMA past president, said drugs required for long-term use should be subsidised or declared as controlled items with fixed profit margins.

Universiti Sains Malaysia (School of Pharmaceutical Sciences) Assoc Prof Mohamed Azmi Ahmad Hasalli said the prices of branded and generic drugs mainly for cardiovascular diseases, cholesterol lowering, diabetes, female hormone condition, allergies and gastrointestinal and respiratory ailments had risen between 5% and 25%.

“The lack of a price control mechanism has caused drug prices to escalate faster than in a developed nation,” he said.

He said the situation was worse now than it was in 2012 when he published a report on a study he made comparing retail drug prices in Penang and Australia.

The report in the Journal of Pharmaceutical Health Services Research said the average retail price of the 10 most prescribed drugs in Penang was between 30.3% and 148.3% higher than in Australia.

While admitting that some drugs “may be pricier now” because of factors like higher currency exchange, PhAMA president Yew Wei Tarng said that “overall drugs in Malaysia are still cheaper than in neighbouring countries”.

PhAMA represents 44 drug companies.

According to Yew, it was unfair to say that the whole pharmaceutical industry had raised prices.

“We know of companies that have not raised prices in years,” he said.

“Based on a recent industry survey, the turnover growth up to September is only 3.15%,” he added

Mehhhhh !!!!
How about you sharing some opinions instead?

If I get u correctly, u are implying that Hovid's revenue growth has been sub-par/below industry average?

But...even CCMDBIO's sales growth also <10% wor...then, who're the average/above average ones?

If I get u correctly, u are implying that Hovid's revenue growth has been sub-par/below industry average?
==> What does the track record shows?

river.sand made a comment about last fiscal year performance. Was it valid?

I do not imply anything.
Best you make your own reasoning.

Read PhaMA's statement.

It represent 44 drug companies.......

That's a lot of fish in the pond.

The articles states of HIGH medicine prices but PhaMA rebutes that statement stating it's unfair to imply that all companies have raised their prices.
Some haven't.

Therefor the question you need to ask is it wise to assume that with high medicine prices, does it mean that all pharmaceutical companies will benefit?

Hi guys, just want to give you some interesting read on a Japanese day trader called CIS, whose stryr featured in Bllomberg news a while back:

http://www.bloomberg.com/news/2014-09-25/m...ion-trades.html

Points to note:

1) Fundamentals is useless in short term intra-day trading.

2) He monitors top 300 most traded stocks...

3) He said 'buy when people are buying and sell when people are selling'...

4) Hes an obvious momentum trader...means he monitor if theres a sudden big volume of bidding or selling price coming...he follows the big money when it enters and when it goes out.

5) Let his winner rides and cut his losers fast.

6) Complicated technical analysis or fundamentals waste your time in analyzing and executing....he prefers the numbers on the market to tell the story and re3acts within seconds....

Im a noob in stock market so pls spare me from any bad bashing uncle gark or pink spider  gor...

Pharma companies earnings not too volatile quater to quarter la

Revenue still growing, 5-6% growth so should be sustainable.  Weak Ringgit should do them good in coming quarters

Do u think good for buy and hold?

If I get u correctly, u are implying that Hovid's revenue growth has been sub-par/below industry average?

But...even CCMDBIO's sales growth also <10% wor...then, who're the average/above average ones?